Aviadobio announces aspire-ftd phase 1/2 clinical trial in the uk at cambridge university hospitals nhs foundation trust, cardiff and vale university health board, and university college london

London--(business wire)--aviadobio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced that its phase 1/2 aspire-ftd clinical trial is now open in the uk. the trial is evaluating avb-101, an investigational gene therapy, in people with frontotemporal dementia (ftd) with grn gene mutations (ftd-grn). cambridge university hospitals nhs foundation trust (cuh), which hosts an internationally.
VALE Ratings Summary
VALE Quant Ranking